医学
疾病
克罗恩病
纤维化
内科学
胃肠病学
重症监护医学
作者
Riccardo Mager,Giulia Roda,Mohammad Shalaby,Stefania Vetrano
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2021-02-17
卷期号:22 (2): 241-251
被引量:7
标识
DOI:10.2174/1389450121666201020160803
摘要
Fibrotic strictures are one of the most severe complications of Crohn’s Disease (CD). They occur in about 50% of patients at five years and in 70% at ten years of the diagnosis. The only treatment available for symptomatic fibrotic strictures is surgical resection and endoscopic dilation. Both strategies are associated with a high rate of recurrence, and with multiple surgical resections, which pose the threat of surgical morbidity and short bowel syndrome. Therefore, it is crucial to identify, early, the patients more prone to develop intestinal fibrosis to intensify follow-ups, switch to more aggressive treatments, and suggest lifestyle modifications. Scarce data are available concerning biomarkers and genetic determinants to predict which patient will develop intestinal fibrosis. Biologic or clinical markers would be useful to determine this subgroup of CD patients and to predict the onset of intestinal fibrosis and, ideally, its severity. Furthermore, the identification of environmental risk factors may suggest lifestyle changes aimed at modifying the natural course, thus decreasing the risk of complicated CD. In this review, we will critically revise clinical, environmental, genetic, and serologic factors that have been associated with a complicated CD course with a particular focus on the fibrostenosing phenotype and their possible implications as predictive factors of intestinal fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI